TY  - JOUR
AU  - de la Cruz-Merino, L
AU  - Gion, M
AU  - Cruz, J
AU  - Alonso-Romero, J L
AU  - Quiroga, V
AU  - Moreno, F
AU  - Andrés, R
AU  - Santisteban, M
AU  - Ramos, M
AU  - Holgado, E
AU  - Cortés, J
AU  - López-Miranda, E
AU  - Cortés, A
AU  - Henao, F
AU  - Palazón-Carrión, N
AU  - Rodriguez, L M
AU  - Ceballos, I
AU  - Soto, A
AU  - Puertes, A
AU  - Casas, M
AU  - Benito, S
AU  - Chiesa, M
AU  - Bezares, S
AU  - Caballero, R
AU  - Jiménez-Cortegana, C
AU  - Sánchez-Margalet, V
AU  - Rojo, F
PY  - 2022
DO  - 10.1186/s12885-022-10363-3
UR  - http://hdl.handle.net/10668/20284
T2  - BMC cancer
AB  - We evaluated a new chemoimmunotherapy combination based on the anti-PD1 monoclonal antibody pembrolizumab and the pyrimidine antimetabolite gemcitabine in HER2- advanced breast cancer (ABC) patients previously treated in the advanced setting, in order...
LA  - en
KW  - Advanced breast cancer
KW  - Chemotherapy
KW  - HER2-negative
KW  - MDSCs
KW  - PD-L1
KW  - Pembrolizumab
KW  - TILs
KW  - Female
KW  - Humans
KW  - Middle Aged
KW  - B7-H1 Antigen
KW  - Breast
KW  - Breast Neoplasms
KW  - Gemcitabine
TI  - Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015-04 (PANGEA-Breast) study.
TY  - research article
VL  - 22
ER  -